1
|
Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. PSYCHOTHERAPY AND PSYCHOSOMATICS 2021; 89:283-306. [PMID: 32259826 DOI: 10.1159/000506868] [Citation(s) in RCA: 110] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Accepted: 02/27/2020] [Indexed: 11/19/2022]
Abstract
Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63-71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. All these drugs may induce withdrawal syndromes and rebound upon discontinuation, even with slow tapering. However, only selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, and antipsychotics were consistently also associated with persistent post-withdrawal disorders and potential high severity of symptoms, including alterations of clinical course, whereas the distress associated with benzodiazepines discontinuation appears to be short-lived. As a result, the common belief that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature. Ketamine, and probably its derivatives, may be classified as at high risk for dependence and addiction. Because of the lag phase that has taken place between the introduction of a drug into the market and the description of withdrawal symptoms, caution is needed with the use of newer antidepressants and antipsychotics. Within medication classes, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, and quetiapine are more likely to induce withdrawal. The likelihood of withdrawal manifestations that may be severe and persistent should thus be taken into account in clinical practice and also in children and adolescents.
Collapse
Affiliation(s)
- Fiammetta Cosci
- Department of Health Sciences, University of Florence, Florence, Italy, .,Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands,
| | - Guy Chouinard
- Clinical Pharmacology and Toxicology Program, McGill University and Mental Health Institute of Montreal Fernand Seguin Research Centre, University of Montreal, Montreal, Québec, Canada
| |
Collapse
|
2
|
|
3
|
Abstract
BACKGROUND Although insomnia is highly prevalent, sleep disturbances often go unrecognized and untreated. When insomnia is recognized, considerable emphasis has been placed on improving sleep onset; however, there is growing evidence that improving sleep maintenance is an equally important treatment goal. METHODS A MEDLINE literature search was performed using the search parameters "insomnia," "zolpidem," "zaleplon," "flurazepam," "estazolam," "quazepam," "triazolam," and "temazepam," as these agents are FDA-approved for the treatment of insomnia. Per reviewer comments, the search criteria was later expanded to include lorazepam. A literature search using the terms "trazodone" and "insomnia" was also performed, as this is the second-most commonly prescribed agent for treating insomnia. Sleep efficacy endpoints from randomized, placebo-controlled clinical trials in adult populations and key review articles published between 1975 and 2004 were included in this review. As only one randomized placebo-controlled trial evaluated trazodone use in primary insomnia, the trazodone search was expanded to include all clinical trials that evaluated trazodone use in insomnia. Relevant texts and other articles that evaluated side effect profiles of these agents were also included, one of which was published in January of 2005. In all publications, impact of treatment on sleep maintenance parameters (wake time after sleep onset, number of awakenings) and measures of next-day functioning were evaluated, in addition to sleep onset parameters (sleep latency, time to sleep onset/induction) and sleep duration data (total sleep time). RESULTS Many of the currently available agents used to treat insomnia, including the antidepressant trazodone, the non-benzodiazepine hypnotics zolpidem and zaleplon, and some of the benzodiazepines, have not consistently demonstrated effectiveness in promoting sleep maintenance. Furthermore, the benzodiazepines with established sleep maintenance efficacy are associated with next-day sedation, the risk of tolerance and dependence, or both. CONCLUSIONS New agents that offer relief of sleep maintenance insomnia without residual next day impairment while improving next day function are needed. Several compounds currently under development may offer clinicians a more effective and safer treatment for this common disorder.
Collapse
|
4
|
Abstract
Approximately one half of patients with insomnia have a primary psychiatric disorder such as a depression or anxiety. Insomnia is associated with increased risk of new or recurrent psychiatric disorders, increased daytime sleepiness with consequent cognitive impairment, poorer prognoses, reduced quality of life and high healthcare-related financial burden. Emerging data suggest that resolution of insomnia may improve psychiatric outcomes, which underscores the importance of vigorous treatment. Unfortunately, only a small percentage of patients receive such care. An ideal monotherapeutic strategy would treat both depression and insomnia. There are, however, only a handful of modern antidepressants that objectively improve sleep maintenance problems, and none do so without causing adverse next-day effects such as sedation. Thus, a significant number of patients must take adjunctive hypnotic medications, even though longer-term efficacy has not been established. New and emerging anti-insomnia agents may prove useful in the long-term treatment of chronic insomnia. Further research is needed to establish the benefits of such treatment.
Collapse
Affiliation(s)
- Michael E Thase
- Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2593, USA.
| |
Collapse
|
5
|
Shinomiya K, Inoue T, Utsu Y, Tokunaga S, Masuoka T, Ohmori A, Kamei C. Hypnotic Activities of Chamomile and Passiflora Extracts in Sleep-Disturbed Rats. Biol Pharm Bull 2005; 28:808-10. [PMID: 15863883 DOI: 10.1248/bpb.28.808] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In the present study, we investigated hypnotic activities of chamomile and passiflora extracts using sleep-disturbed model rats. A significant decrease in sleep latency was observed with chamomile extract at a dose of 300 mg/kg, while passiflora extract showed no effects on sleep latency even at a dose of 3000 mg/kg. No significant effects were observed with both herbal extracts on total times of wakefulness, non-rapid eye movement (non-REM) sleep and REM sleep. Flumazenil, a benzodiazepine receptor antagonist, at a dose of 3 mg/kg showed a significant antagonistic effect on the shortening in sleep latency induced by chamomile extract. No significant effects were observed with chamomile and passiflora extracts on delta activity during non-REM sleep. In conclusion, chamomile extract is a herb having benzodiazepine-like hypnotic activity.
Collapse
Affiliation(s)
- Kazuaki Shinomiya
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan
| | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
Ceiling and floor effects dictate that the efficacy of sleep-promoting stimuli should be proportional to the degree of pre-stimulus sleep impairment. This review addressed CF effects in polysomnographic research involving hypnotic drugs and exercise. Correlations of placebo/baseline levels of sleep with changes in sleep following hypnotic or exercise treatment were assessed across both literatures. CF effects were further addressed by comparing sleep-promoting effects of hypnotics vs exercise, after ANCOVA control for substantial baseline differences reported in studies of these stimuli. Significant correlations between placebo-baseline levels and sleep changes were observed following both hypnotic and exercise stimuli. Indeed, approximately 60% of the variance in improvement in sleep latency (SOL), wakefulness after sleep onset (WASO) and total sleep time (TST) following hypnotic treatment was associated with differences in baseline levels. ANCOVAs revealed significantly greater decreases in SOL and WASO following hypnotics compared with exercise. However, no significant difference between stimuli was found for TST, and exercise elicited a significantly greater increase in slow wave sleep. Similar results were found when a comparison between hypnotics and exercise was limited to good sleepers. The results show powerful CF influences on sleep responses to hypnotics and exercise and suggest a need for comparing these treatments in poor sleepers.
Collapse
Affiliation(s)
- Shawn D Youngstedt
- Department of Psychiatry and Sam and Rose, Stein Institute for Research on Aging, University of California, San Diego, California 92093-0667, USA.
| |
Collapse
|
7
|
Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB. Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. J Clin Psychopharmacol 1995; 15:259-62. [PMID: 7593708 DOI: 10.1097/00004714-199508000-00004] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
This study was designed to evaluate the relative and absolute bioavailability of triazolam, 0.25 mg, after the administration of the marketed oral tablet and a sublingual prototype wafer; an intravenous dose was used as a reference. Twelve men were evaluated in a three-way crossover study; study days were separated by 1 week. A single dose was administered to each subject at approximately 8 a.m.; serial blood samples were obtained for the determination of triazolam concentration. The fraction absorbed relative to intravenous was 20% higher in the sublingual than in the oral treatment (p = 0.0128); the difference between treatments was greatest in the first 2 hours as indicated by the area under the curve from 0 to 2 hours (p < 0.05). The extraction ratio ranged from 0.05 to 0.25, and the predicted availability after oral administration was 86% with a range of 75 to 95%. In contrast, the observed mean absolute availability was 44% (oral) and 53% (sublingual). A potential explanation for this discrepancy between predicted and observed bioavailability is that after oral administration, a fraction of triazolam may be metabolized by cytochrome P450IIIA4 in the gut wall, with a separate fraction subject to first-pass metabolism in the liver. Although this study was not designed to identify sites of triazolam metabolism, the proposed explanation is consistent with the occurrence of P450IIIA4 in the stomach, small intestine, and liver. Doses administered sublingually avoid first-pass metabolism, producing earlier and higher peak concentrations than do doses administered orally.
Collapse
Affiliation(s)
- P D Kroboth
- University of Pittsburgh Pharmacodynamic Research Center, Pennsylvania 15261, USA
| | | | | | | | | |
Collapse
|
8
|
Declerck AC, Ruwe F, O'Hanlon JF, Vermeeren A, Wauquier A. Effects of zolpidem and flunitrazepam on nocturnal sleep of women subjectively complaining of insomnia. Psychopharmacology (Berl) 1992; 106:497-501. [PMID: 1579623 DOI: 10.1007/bf02244821] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Eighteen non-pregnant woman complaining about insomnia were polysomnographically investigated for 3 nights with weekly intervals. They received placebo, 2 mg flunitrazepam or 10 mg zolpidem according to a cross-over double blind design. The patients were selected by general practitioners on the basis of subjective complaints. Zolpidem is a recently introduced short-acting imidazopyridine hypnotic, binding to a subunit of the benzodiazepine 1 receptor. Flunitrazepam is a well-known hypnotic, binding to both the benzodiazepine 1 and 2 receptor subtypes. Objective recording did not substantiate the subjective complaint of insomnia. Sleep patterns during placebo differed only little from that expected from age matched healthy persons. Both flunitrazepam and zolpidem significantly shortened sleep onset (5 min of continuous sleep beginning with NREM 1 sleep). The sleep composition following flunitrazepam was characterized by an increase in NREM 2, a prolongation of the time of REM sleep, a reduction of REM sleep and an increase in NREM 3-4 sleep during the first 2 h of sleep. The sleep composition following zolpidem resembled more than seen in persons without sleep complaints. However, as compared to placebo, there was a decrease of the time spent awake during sleep and an increase in NREM 3-4 during the first 2 of sleep.
Collapse
Affiliation(s)
- A C Declerck
- Epilepsy Center Kemphenhaghe, Department of EEG and Clinical Neurophysiology, Heeze, The Netherlands
| | | | | | | | | |
Collapse
|
9
|
Woo E, Proulx SM, Greenblatt DJ. Differential side effect profile of triazolam versus flurazepam in elderly patients undergoing rehabilitation therapy. J Clin Pharmacol 1991; 31:168-73. [PMID: 2010562 DOI: 10.1002/j.1552-4604.1991.tb03702.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Patients (aged 65 years or older) who were hospitalized for rehabilitation therapy after a cerebrovascular accident or other acute debilitating condition participated in a 6-week controlled clinical trial. After a 2-week period of receiving nightly single-blind placebo, patients were randomly allocated to receive either triazolam (0.125 mg) or flurazepam hydrochloride (15 mg) nightly under double-blind conditions. For the final 2 weeks, patients again received single-blind placebo. The study groups' were comparable in their performance on four psychomotor tests done in the morning during the initial placebo period. Triazolam-treated patients showed subsequent improvement on the tests, consistent with practice effects, whereas flurazepam recipients showed performance impairment during treatment. Triazolam-flurazepam differences were significant in the card-sorting and arithmetic tests, and they approached significance for the Purdue pegboard test. Blind ratings by physical therapists indicated significant impairment among flurazepam recipients in their capacity to cooperate with and participate in the rehabilitation tasks; the impairment persisted into the post-treatment placebo period. Similar flurazepam-triazolam differences, although not significant, were reported by occupational therapy and nursing staff members. The findings suggest that the kinetic differences between flurazepam and triazolam may have clinical implications in elderly patients undergoing rehabilitation therapy.
Collapse
Affiliation(s)
- E Woo
- Department of Medicine, Spaulding Rehabilitation Hospital, Boston, Massachusetts
| | | | | |
Collapse
|
10
|
Mamelak M, Csima A, Price V. The effects of a single night's dosing with triazolam on sleep the following night. J Clin Pharmacol 1990; 30:549-55. [PMID: 2355105 DOI: 10.1002/j.1552-4604.1990.tb03619.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
This study was undertaken to determine whether a single night's use of triazolam by normal healthy sleepers leads to withdrawal insomnia on the subsequent night, and whether there is a dose response relationship to this phenomenon. Thirty normal sleepers of both sexes were randomly assigned to three parallel treatment groups. All subjects were studied for five consecutive nights by means of pre- and post-sleep questionnaires and all night polysomnography. Multiple sleep latency tests were conducted on the days following the second, third, and fourth nights in the laboratory. All subjects received placebo capsules on the first, second, fourth, and fifth nights in the laboratory and either placebo, 0.25 mg triazolam or 0.5 mg triazolam according to their assigned group on the third night. Both doses of the drug increased subjective estimates of sleep duration, but no objective increase was found. Neither dose altered daytime measures of sleepiness. No changes were found in any of the sleep parameters on withdrawal of the 0.25 mg dose of triazolam. However, discontinuation of the 0.5 mg dose did lead to significant objective and subjective withdrawal effects. It was concluded that higher doses of triazolam could lead to withdrawal effects in normal sleepers even when this drug was used for only a single night.
Collapse
Affiliation(s)
- M Mamelak
- Department of Psychiatry, Sunnybrook Medical Centre, University of Toronto, Ontario
| | | | | |
Collapse
|
11
|
Affiliation(s)
- D J Greenblatt
- Division of Clinical Pharmacology, Tufts University School of Medicine, Boston, MA
| | | | | |
Collapse
|
12
|
Luyk NH, Weaver JM, Beck FM, Loetscher CA, Sacks J. The effectiveness of flurazepam as night sedation prior to the removal of third molars. Int J Oral Maxillofac Surg 1988; 17:347-51. [PMID: 3145948 DOI: 10.1016/s0901-5027(88)80060-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Anxiety prior to dental treatment is a well-recognized problem. Although oral sedation has been recommended the night before appointments to reduce this anxiety, there are no well-controlled studies to support this claim. The present double-blind cross-over study investigated the effect of 30 mg of flurazepam taken the night before the removal of impacted third molars. Preoperative anxiety, visuomotor performance and sleep patterns were investigated in 20 adult patients with similarly impacted third molars. While preoperative flurazepam led to a statistically significant improvement in sleep patterns, there was no reduction in pre-operative anxiety on the morning of surgery. In addition, the flurazepam-treated group demonstrated significantly impaired visuo-motor performance 60 min after intravenous sedation compared to this group where intravenous sedation was used only preceded by placebo. Patients had a significant preference for flurazepam over placebo as a night-time sedative.
Collapse
Affiliation(s)
- N H Luyk
- Section of Oral and Maxillofacial Surgery, College of Dentistry, Ohio State University, Columbus 43210
| | | | | | | | | |
Collapse
|
13
|
Higgitt A, Fonagy P, Lader M. The natural history of tolerance to the benzodiazepines. PSYCHOLOGICAL MEDICINE. MONOGRAPH SUPPLEMENT 1988; 13:1-55. [PMID: 2908516 DOI: 10.1017/s0264180100000412] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Dependence on benzodiazepines following continued use is by now a well-documented clinical phenomenon. Benzodiazepines differ in their dependence potential. The present studies were aimed at examining the possibility that differential rates of tolerance development might account for differences in dependence risk. Four studies are reported. The first three studies concerned normal subjects. The development of tolerance over a fifteen day period was demonstrated for three different benzodiazepines (ketazolam, lorazepam and triazolam) using two paradigms. Tolerance in terms of a reduction in effectiveness of a repeated given dose was most notable for the benzodiazepine with a medium elimination half-life (lorazepam) for physiological, behavioural and subjective measures. In the case of the drug with the longest elimination half-life (ketazolam) reduction in effectiveness could only be assumed to be occurring if account was taken of the steady increase in plasma concentrations of active metabolites. For this drug it seemed that the physiological measures were those most likely to demonstrate the development of tolerance. Although triazolam showed few significant drug effects on this paradigm (testing being 12 hours after ingestion of this short half-life benzodiazepine), tolerance was seen to develop on some subjective measures. Using an alternative method of testing tolerance, assessing responses to a diazepam challenge dose, a high degree of tolerance on two-thirds of the measures was observed in subjects when pretreated with the benzodiazepine with the most marked accumulation of active metabolites (ketazolam). The other two drugs also led to tolerance development on a range of measures; this was more marked for lorazepam than triazolam. Blunting of the growth hormone response to diazepam was the most sensitive and reliable method of detecting tolerance to the benzodiazepines. Symptoms on discontinuation of the two weeks' intake of the benzodiazepines were marked for all the drugs but unrelated to either the tolerance induced or the elimination half-life of the particular drug. A further clinical study revealed that tolerance persisted in a group of long-term benzodiazepine users for between four months and two years following complete abstinence from the drug. These patients appeared to be less affected by diazepam in terms of its commonly observed subjective effects, regardless of their original medication. These ex-long-term users of benzodiazepines were, however, more likely to manifest two specific types of effects--immediate 'symptom' reduction and exacerbation of 'withdrawal symptoms' over the subsequent week.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- A Higgitt
- Department of Psychiatry, St Mary's Hospital, London
| | | | | |
Collapse
|
14
|
Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 1987; 317:722-8. [PMID: 3306380 DOI: 10.1056/nejm198709173171202] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Sixty volunteers with insomnia participated in a randomized, double-blind, controlled clinical trial. After an initial six nights of placebo, 30 subjects (the abrupt-withdrawal group) received 0.5 mg of triazolam nightly for 7 to 10 nights, after which they received placebo. The other 30 subjects (the tapered-dosage group) received the same initial placebo treatment, then triazolam at 0.5 mg for seven nights, at 0.25 mg for two nights, and at 0.125 mg for two nights, and then placebo. As compared with the initial placebo period, the triazolam period significantly reduced the interval before the onset of sleep (sleep latency), and it prolonged sleep duration, reduced the number of awakenings, and improved the self-rated soundness of sleep in all cohorts. In the abrupt-withdrawal group, plasma levels of triazolam were undetectable the morning after the first night of placebo substitution, and subjects reported prolongation of sleep latency (57 minutes longer than base line), reduction in sleep duration (1.4 hours less than base line), and increased awakenings (1.2 per night above base line). The symptoms of rebound sleep disorder lasted one or possibly two nights, and there was a reversion toward base line on subsequent placebo nights. In the tapered-dosage group, however, plasma triazolam levels fell gradually to zero, and rebound symptoms were decreased or eliminated. Thus, rebound sleep disorder following abrupt discontinuation of triazolam can be attenuated by a regimen of tapering.
Collapse
|
15
|
Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Manfredi RL. Alprazolam: effects on sleep and withdrawal phenomena. J Clin Pharmacol 1987; 27:508-15. [PMID: 3655003 DOI: 10.1002/j.1552-4604.1987.tb03058.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Alprazolam was evaluated in chronic insomniacs in a 1-mg bedtime dose. The 16-night sleep laboratory protocol included four placebo-baseline nights followed by seven nights of drug administration and five placebo-withdrawal nights. On the first three drug nights (nights 5 to 7), the drug was highly effective in inducing and maintaining sleep with this short-term use. By the end of the one week of administration (nights 9 to 11), however, the drug had lost about 40% of its efficacy. During drug use, one subject reported some difficulty in controlling expression of inappropriate emotions when interacting with others, which suggested the presence of disinhibition. On the third night following drug termination, there was a significant increase in sleep difficulty above baseline levels (rebound insomnia). This worsening was of comparable magnitude to the peak improvement of sleep with drug administration. Thus, the clinical utility of alprazolam when administered to insomniac patients appears to be limited because of a relatively rapid development of tolerance and possible disinhibitory reactions during drug use and the occurrence of rebound insomnia following withdrawal.
Collapse
Affiliation(s)
- A Kales
- Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey
| | | | | | | | | |
Collapse
|
16
|
Soldatos CR, Sakkas PN, Bergiannaki JD, Stefanis CN. Behavioral side effects of triazolam in psychiatric inpatients: report of five cases. DRUG INTELLIGENCE & CLINICAL PHARMACY 1986; 20:294-7. [PMID: 3516616 DOI: 10.1177/106002808602000418] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Triazolam was administered to five psychiatric inpatients for a two-week period. This period was preceded by a one-week placebo baseline and followed by another week of placebo administration. All conditions were double blind. By the second week of active drug administration, psychopathology greatly intensified across all of the patients with the emergence of anxiety, memory impairment, confusion, paranoid ideation, and hallucinations. The drug-induced behavioral changes persisted during the initial withdrawal period, but then gradually subsided. Also following drug withdrawal, four patients showed a marked worsening of their sleeplessness for several nights.
Collapse
|
17
|
Pinnock CA, Fell D, Hunt PC, Miller R, Smith G. A comparison of triazolam and diazepam as premedication agents for minor gynaecological surgery. Anaesthesia 1985; 40:324-8. [PMID: 2860819 DOI: 10.1111/j.1365-2044.1985.tb10784.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Triazolam 0.25 mg, diazepam 10 mg and placebo were compared in a randomized double-blind trial of oral premedication in 90 patients undergoing minor gynaecological surgery. Both triazolam and diazepam produced a significant sedative effect as measured by patient self assessment linear analogue scales but only diazepam was more anxiolytic than placebo. Psychomotor performance assessed by the letter-search test at 3 and 6 hours after awakening showed a decrement in performance in patients receiving triazolam at 3 hours compared with the two other groups. Triazolam was shown to have a pronounced amnesic effect and whilst it might be used for premedication, its lack of anxiolysis coupled with a significant impairment of psychomotor performance at 3 hours after awakening, render the drug unsuitable for premedication in the short stay patient.
Collapse
|
18
|
Griffiths RR, Lamb RJ, Ator NA, Roache JD, Brady JV. Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 1985; 9:133-51. [PMID: 2858078 DOI: 10.1016/0149-7634(85)90039-9] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The abuse liability of a drug is a positive, interactive function of the reinforcing and adverse effects of the drug. The relative abuse liability of the hypnotic benzodiazepine, triazolam, has been controversial. This paper reviews animal and human studies bearing on its relative abuse liability, including data on pharmacological profile, reinforcing effects, liking, speed of onset, discriminative stimulus effects, subjective effects, physiological dependence, rebound and early morning insomnia, drug produced anxiety, lethality in overdose, psychomotor impairment, interactions with ethanol, anterograde amnesia, impaired awareness of drug effect, and other psychiatric and behavioral disturbances. It is concluded that the abuse liability of triazolam is less than that of the intermediate duration barbiturates such as pentobarbital. Although there are considerable data indicating similarities of triazolam to other benzodiazepines, there is also substantial speculation among clinical investigators and some limited data suggesting that the abuse liability of triazolam is greater than that of a variety of other benzodiazepines, and virtually no credible data or speculation that it is less. Further research will be necessary to clarify definitively the abuse liability of triazolam relative to other benzodiazepines.
Collapse
|
19
|
Bixler EO, Kales JD, Kales A, Jacoby JA, Soldatos CR. Rebound insomnia and elimination half-life: assessment of individual subject response. J Clin Pharmacol 1985; 25:115-24. [PMID: 2859304 DOI: 10.1002/j.1552-4604.1985.tb02811.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Following abrupt withdrawal of five benzodiazepine hypnotics, the presence of rebound insomnia on individual subject nights was evaluated in comparison to a placebo group. During the first three nights of withdrawal, the frequency of occurrence of rebound insomnia for drugs with relatively rapid rates of elimination (triazolam, midazolam, and lormetazepam) was significantly higher than that for the placebo control group. In contrast, the frequency of withdrawal sleep difficulty for two slowly eliminated hypnotics (flurazepam and quazepam) was similar to that of the placebo control group during each of five successive three-night segments of a 15-night withdrawal period. These findings, based on individual subject-night data, confirm and extend previous reports using group mean values that demonstrate a frequent, immediate, and intense degree of rebound insomnia following abrupt withdrawal of relatively rapidly eliminated hypnotic drugs and an infrequent, delayed, and milder degree of sleep difficulty following withdrawal of slowly eliminated drugs.
Collapse
|
20
|
Mamelak M, Csima A, Price V. A comparative 25-night sleep laboratory study on the effects of quazepam and triazolam on chronic insomniacs. J Clin Pharmacol 1984; 24:65-75. [PMID: 6143767 DOI: 10.1002/j.1552-4604.1984.tb02767.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The short- and intermediate-term actions, as well as the carryover and withdrawal effects, of quazepam , a new benzodiazepine hypnotic with a half-life of 60 to 100 hours, were compared with those of triazolam, a triazolodiazepine hypnotic with a half-line of 2 to 3 hours. Both the subjective effects of these drugs as well as their objective actions on the sleep EEG were sought. The study was conducted on two groups of six subjects with chronic insomnia who ranged in age from 32 to 56 years. Each subject was studied for 25 consecutive nights. Placebo was administered at bedtime on the first four nights, followed by 30 mg quazepam or 0.5 mg triazolam on the next 14 nights and by placebo again on the ensuing seven withdrawal nights. Both drugs increased the total sleep time during their administration and improved the subjective quality of sleep. Major differences, however, were observed on withdrawal. A significant and marked decrease in the total sleep time occurred with triazolam on the first withdrawal night. With quazepam , rebound insomnia was not observed at any time during the seven-day withdrawal period.
Collapse
|
21
|
Vogel GW. Sleep laboratory study of lormetazepam in older insomniacs. PSYCHOPHARMACOLOGY. SUPPLEMENTUM 1984; 1:69-78. [PMID: 6147842 DOI: 10.1007/978-3-642-69659-6_5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Lormetazepam is a new benzodiazepine hypnotic. Previous work has indicated that lormetazepam has an intermediate to short elimination half-life, i.e. in the range of 5-15 h. Hence, in older patients, the drug should be safe and hypnotically active in doses equal to or less than the doses recommended for young adults. The present study tested this hypothesis. We studied ten healthy subjects, aged 55 and older, with both subjective and objective insomnia. Subjective insomnia was the complaint of requiring at least 45 min to fall asleep and sleeping less than six and a half hours per night. Each complaint was present on at least 50% of the nights for at least three months. Objective insomnia was measured polysomnographically and was present on at least two of the last three nights of four consecutive nights of placebo baseline. The study involved a design in which treatment was administered in a double-blind fashion. Each subject was studied for 14 consecutive nights in the sleep laboratory. The drug was administered for seven consecutive nights which were preceded by a placebo baseline and followed by a placebo period of drug withdrawal. On each laboratory night subjects were monitored by continuous, all-night conventional EEG/EOG/EMG recordings. Each laboratory morning subjects completed a questionnaire on which they rated six characteristics of their sleep on the previous night. At study entry and again at study end, each subject had a physical examination by a Board internist and clinical laboratory tests. Each laboratory morning and evening subjects had a screening physical exam and completed an 11-item hypnotic drug side-effect questionnaire and a 56-item review of medical systems questionnaire. Compared with the median baseline night, on the median drug night lormetazepam 0.5 mg significantly increased total sleep time by about 25 min. The drug's reductions of sleep latency were substantial. In addition, lormetazepam 0.5 mg significantly decreased number of awakenings. No objective evidence was found of either tolerance developing to the hypnotic efficacy of lormetazepam 0.5 mg or of rebound insomnia.
Collapse
|
22
|
Adam K, Oswald I, Shapiro C. Effects of loprazolam and of triazolam on sleep and overnight urinary cortisol. Psychopharmacology (Berl) 1984; 82:389-94. [PMID: 6145179 DOI: 10.1007/bf00427692] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Nine poor sleepers of mean age 61 years were studied while they took loprazolam 0.5 mg, loprazolam 1 mg and triazolam 0.5 mg for 3-week periods. Loprazolam 1 mg and triazolam 0.5 mg increased sleep duration, but there was some tolerance to both, particularly triazolam, by the 3rd week. Withdrawal of either drug led to sleep significantly shorter than baseline. This rebound effect was significant greater than withdrawing triazolam. After withdrawing loprazolam 1 mg, the rebound was maximal on the 3rd night and after withdrawing triazolam it was maximal and severe on the 1st night. In the third week of use neither drug was associated with late-night wakefulness. Total overnight urinary cortisol was lower during drug intake and there were significant withdrawal rebounds to above baseline levels, immediately so after triazolam.
Collapse
|
23
|
|
24
|
Abstract
Triazolam is a sedative/hypnotic triazolobenzodiazepine, structurally related to alprazolam. Recently, it has been approved for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Triazolam is metabolized with a half-life of 1.5-5.0 hours. Its one active metabolite, which appears in low concentrations and is inactivated rapidly, is not thought to contribute to its pharmacologic activity. Triazolam has been shown to decrease sleep latency and the number of nocturnal awakenings while increasing total sleep time in patients with insomnia. Sleep electroencephalogram studies show that triazolam has no effect on delta-sleep (Stages 3 and 4) and has variable effects on rapid-eye-movement sleep. Nighttime administration of triazolam increases daytime alertness in insomniacs and improves or has no effect on performance. The reported side effects are similar to those of other benzodiazepines and include drowsiness, dizziness, and dry mouth. The recommended dosage of triazolam is 0.25-0.5 mg hs. A reduced initial dose of 0.125 mg should be used in geriatric patients.
Collapse
|
25
|
|
26
|
Abstract
Triazolam is a new triazolobenzodiazepine drug that is indicated for the treatment of insomnia. The usual adult dosage is 0.25 to 0.5 mg; for geriatric patients a dose of 0.125 to 0.25 mg is recommended. Triazolam is readily absorbed and quickly eliminated with a half-life of 2-5 hours, making it the shortest acting benzodiazepine available in the United States. Sleep laboratory and non-laboratory clinical trials found triazolam 0.25 and 0.5 mg effective in inducing and maintaining sleep. It remained effective in laboratory studies of up to one month duration and non-laboratory studies of up to six months duration when the drug was administered nightly. On discontinuation disturbed sleep for one or two nights was observed in some studies. Triazolam impairs performance for several hours after administration. However, unlike benzodiazepines with long-acting metabolites, triazolam is relatively free of daytime residual effects, which is attributable to its short half-life. Overall, triazolam is an effective and safe compound for the symptomatic treatment of insomnia complaints.
Collapse
|
27
|
Vogel GW. Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7:343-9. [PMID: 6684318 DOI: 10.1016/0278-5846(83)90122-7] [Citation(s) in RCA: 70] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
In the treatment of endogenous depression REM sleep deprivation and imipramine have similar efficacy. Across drugs, efficacy of antidepressant activity is directly related to capacity of drugs to produce large and sustained reductions of REM sleep. Endogenous depression unimproved by REM sleep deprivation is unimproved by imipramine. Endogenous depression improvement by REM sleep deprivation and by amitriptyline have the same biological correlate, viz, REM rebound. In animals REM sleep deprivation produces several behavioral changes (e.g., increased motor, sexual, aggressive, pleasure seeking, feeding activities) which are the reverse of behavioral changes of human endogenous depression.
Collapse
|
28
|
Gorenstein C, Gentil V. Residual and acute effects of flurazepam and triazolam in normal subjects. Psychopharmacology (Berl) 1983; 80:376-9. [PMID: 6137859 DOI: 10.1007/bf00432125] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Residual and acute effects of flurazepam and triazolam were studied in two double-blind, crossover, placebo controlled, single-dose experiments. Psychological and physiological effects were determined 10 h after night administration (flurazepam 30 mg and triazolam 0.5 mg), and for 6 h after morning ingestion (flurazepam 15 mg and triazolam 0.25 mg). Both drugs produced similar "hangover" effects, impairing motor performance and increasing sleepiness on the following morning. After morning administration pronounced sedative effects were found with triazolam, while flurazepam effects were mild and hard to distinguish from placebo. The clinical relevance of these findings is discussed, suggesting that these drugs may be conceived as belonging to two different types of hypnotic agents.
Collapse
|
29
|
Vela-Bueno A, Oliveros JC, Dobladez-Blanco B, Arrigain-Ijurra S, Soldatos CR, Kales A. Brotizolam: a sleep laboratory evaluation. Eur J Clin Pharmacol 1983; 25:53-6. [PMID: 6617724 DOI: 10.1007/bf00544014] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Brotizolam 0.25 mg was evaluated in a sleep laboratory study of 10 normal subjects. The study covered 10 consecutive nights and included 4 placebo-baseline nights, 3 nights on the drug and 3 placebo-withdrawal nights, which permitted assessment of initial drug effects, side effects and withdrawal phenomena, such as rebound insomnia. There was a significant increase in total sleep time with drug administration; the improvement in sleep occurred primarily in the first third of the night following the onset of sleep. During the day after nightly drug administration, the presence of rebound anxiety was suggested by an increase in reports of anxiety/tension as compared to baseline. Following drug withdrawal there was a significant increase in total wake time above baseline level, to 40% above baseline on the first and third nights of withdrawal.
Collapse
|
30
|
Abstract
We studied in a sleep laboratory the effects of bedtime 15 mg midazolam and 20 mg midazolam on the sleep and morning performance of healthy subjects with polygraphically verified sleep onset insomnia. Six subjects received 15 mg midazolam and six subjects received 20 mg midazolam for 14 consecutive nights which were preceded by a three-night placebo baseline and followed by a three-night placebo period. The medications were administered in a double-blind manner. The results were that both doses increased total sleep time, reduced sleep latency, reduced wake time after sleep onset and reduced the number of awakenings. There was no difference between the doses. Midazolam had its main effect by decreasing wake time in the first third of the night. We found no evidence of tolerance, drug withdrawal rebound insomnia, or drug-induced morning performance decrements. We did find evidence of an anterograde amnesia produced by the drug.
Collapse
|
31
|
Kales A, Bixler EO, Soldatos CR, Mitsky DJ, Kales JD. Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia. J Clin Pharmacol 1982; 22:520-30. [PMID: 6131080 DOI: 10.1002/j.1552-4604.1982.tb02645.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Lormetazepam, an investigational hypnotic, was evaluated for efficacy and withdrawal phenomena in doses of 0.5, 1.0, 1.5, and 2.0 mg in four separate sleep laboratory protocols, each including four placebo baseline nights, seven drug nights, and three placebo withdrawal nights. A moderate degree of efficacy was shown across the four doses, but this was quite variable. There was no dose-response effect for efficacy for either the first three or last three nights of this short-term administration period. In general, there was less efficacy on the later drug nights, indicating a potential for the development of tolerance over a relatively short period of time. Following drug withdrawal, there was a dose-related worsening of sleep above baseline levels (rebound insomnia). The peak degree of worsening of sleep following drug withdrawal was more than two times greater than the peak degree of improvement of sleep with drug administration.
Collapse
|
32
|
Reimão R, Lefévre AB. Evaluation of flurazepam and placebo on sleep disorders in childhood. ARQUIVOS DE NEURO-PSIQUIATRIA 1982; 40:1-13. [PMID: 7046699 DOI: 10.1590/s0004-282x1982000100001] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The clinically observed results in 40 patients, from 1 to 15 years old, presenting sleep disturbances, in a comparative and statistically approached study of flurazepam 15mg daily against placebo, are reported. Placebo was administered, followed by the drug, during 14 days each. The chief complaints were sleepwalking, sleep-talking, sleep terror, sleep-related bruxism, sleep-related headbanging, insomnia and excessive movements during sleep. A significant effect of flurazepam on sleepwalking, sleep-talking, bruxism, sleep terror and excessive movement during sleep, was observed. The insomniac headbanging patients were not enough for statistical analysis. Flurazepam side effects were excessive drowsiness during daytime in 3 cases; irritability, 3 cases; nausea and vomiting, 2 cases, and were not correlated with age. Placebo side effects were similar, except for nausea and vomiting which were not observed. It was necessary to discontinue flurazepam in 2 cases, because of excessive drowsiness during daytime, which did not improve when reducing the dose.
Collapse
|
33
|
Spinweber CL, Johnson LC. Effects of triazolam (0.5 mg) on sleep, performance, memory, and arousal threshold. Psychopharmacology (Berl) 1982; 76:5-12. [PMID: 6123129 DOI: 10.1007/bf00430746] [Citation(s) in RCA: 79] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The effects of a short-acting benzodiazepine hypnotic, triazolam (0.5 mg), on sleep, performance, and arousal threshold were assessed in 20 male poor sleepers (age 21 +/- 2.37 years). Following in a laboratory screening night, all subjects received placebo for 3 nights (single-blind), ten received triazolam and ten placebo for 6 nights (double-blind), and all received placebo on 2 withdrawal nights (single-blind). All effects described below were statistically significant. Triazolam reduced sleep latency and increased total sleep time and sleep efficiency. Percent Stage 2 was increased and percent Stage 4 was reduced during treatment. Morning performance, measured 8.25 h post-drug, showed no decrements. Acute effects were assessed on treatment night 6 during arousals from sleep at 1.5, 3, and 5 h post-administration: performance was impaired in triazolam subjects on the Wilkinson 4-Choice Reaction Time Test, Digit Symbol Substitution Test, Williams Word Memory Test, and Card Sorting Task. In the morning following treatment night 6, long-term memory was tested using a recognition task requiring subjects to identify words presented during night-time test batteries: triazolam subjects correctly identified fewer target words. Triazolam administration produced anterograde amnesic effects. However, in a Paired Associates Test learned prior to drug ingestion on the previous evening, triazolam did not impair morning recall of word pairs. Threshold for arousal from slow wave sleep was elevated during treatment, and triazolam subjects did not show increased sensitivity to the arousing tone over nights as did placebo subjects.
Collapse
|
34
|
Abstract
In 52 studies, performance data were obtained the next day following bedtime ingestion of a sedative-hypnotic or a placebo. Only eight of these studies used insomniac patients. Most studies used young adult males. Benzodiazepine hypnotics were most frequently administered and psychomotor performance was most often measured. Little consistent data are available on cognitive functioning and more complex behavior. Drug-related improvement in performance was not found, and, in comparing active drug to placebo, it is clear that all hypnotics, at some doses, produce decrements in performance the next day. Higher doses consistently showed a decrement, and this decrement was usually persistent over the entire day. Although long-acting drugs generally showed more performance decrement, half-life data were not consistent.
Collapse
|
35
|
Johnson LC, Spinweber CL. Effect of a short-acting benzodiazepine on brain electrical activity during sleep. ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 1981; 52:89-97. [PMID: 6166458 DOI: 10.1016/0013-4694(81)90193-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The effects of the short-acting benzodiazepine, triazolam, on EEG activity during sleep were assessed in poor sleepers. Twenty male subjects, mean age 21 +/- 2.37 years, participated. A screening night preceded 3 placebo nights, 6 treatment nights, and 2 placebo-withdrawal nights. During treatment, 10 subjects received triazolam (0.5 mg) and 10 received placebo. The treatment condition was double-blind. In addition to rate/min spindle count and number of delta half-waves/min, the auditory evoked response (AEP) was obtained on the last placebo baseline and the fifth drug night. Subjects receiving triazolam showed a significant increase in sleep spindles and a significant decrease in delta count during drug administration. Both values returned to baseline on the first withdrawal night. The AEP peak-to-trough amplitude was also significantly reduced during sleep by triazolam, but, as the time since drug ingestion increased, the amplitude of the AEP also increased. There was no difference in AEP amplitude between the two groups 5 h post-drug ingestion.
Collapse
|
36
|
Karacan I, Orr W, Roth T, Kramer M, Thornby J, Bingham S, Kay D. Dose-related effects of flurazepam on human sleep-walking patterns. Psychopharmacology (Berl) 1981; 73:332-9. [PMID: 6789354 DOI: 10.1007/bf00426461] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Two consecutive nights of flurazepam at each of 15, 26, and 45 mg were compared to placebo in a Latin-square double-blind crossover design using 24 healthy young-adult males. Flurazepam had significant hypnotic effects on objective and subjective measures of efficacy: shorter sleep latency, longer sleep time, and fewer awakenings. It also induced morning sedation along with decrements in cognitive performance. Flurazepam had dose-related impacts on both human and computer-scored EEG-EOG parameters: less stages 3 + 4 and decreased EEG delta, less stage 1 REM and decreased REM density, more stage 2 and increased EEG spindling. Also, EEG alpha and movement artifact were decreased and EEG beta was increased. Only a few of the EEG-EOG variables and none of the subjective indices had cumulative changes on the two drug nights. Stage shifting was unaffected at the two lower doses on the first night but decreased at all three dose levels on the second night; percent stages 3 + 4 was unaffected on the first night but decreased at all dose levels on the second night. The rate of delta waveform activity was also diminished by a greater amount on the second night. This study conclusively established that flurazepam affects the EEG-EOG architecture of sleep on each of the first two nights of administration.
Collapse
|
37
|
Abstract
1 The evaluation of an hypnotic may be approached from the view that insomnia is a primary disease or the symptom of an underlying emotional or physical problem. 2 The two approaches have been used in the investigation of triazolam.
Collapse
|
38
|
Dordain G, Puech AJ, Simon P. Triazolam compared with nitrazepam and with oxazepam in insomnia: two double-blind, crossover studies analyzed sequentially. Br J Clin Pharmacol 1981; 11 Suppl 1:43S-49S. [PMID: 6133534 PMCID: PMC1401639 DOI: 10.1111/j.1365-2125.1981.tb01838.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
1 In two double-blind, crossover studies, general practitioners compared the hypnotic activity of triazolam 0.50 mg with that of nitrazepam 5 mg or oxazepam 50 mg in outpatient insomnias. 2 The patient's preferences served as the main criterion, and were processed by sequential analysis. 3 More patients (P less than 0.05) preferred triazolam to nitrazepam (triazolam 28; nitrazepam 11; no preference 9). 4 The numbers of patients who preferred triazolam or oxazepam did not differ significantly. 5 Triazolam and oxazepam affected sleep parameters similarly except for onset of sleep and feeling in the morning, for which triazolam seemed to be superior to oxazepam.
Collapse
|
39
|
Abstract
1 Activity of short- and long-acting benzodiazepines is reviewed with reference to pharmacokinetics and residual sequelae, and to efficacy and adverse effects. 2 Some benzodiazepines may not lead to obvious effects on performance, such as nordiazepam and clobazam, and the persistence of residual sequelae may not relate obviously to elimination half-lives (as with diazepam and possibly flunitrazepam). However, benzodiazepines with mean half-lives less than 8 h may have residual sequelae, whereas hypnotics with mean half-lives greater than 16 h are likely to lead to impared performance and/or anxiolytic effects the next day. 3 Potassium chlorazepate 15 mg, with its long-acting metabolite nordiazepam, would seem to be the drug of choice for insomnia secondary to anxiety. For the insomniac without significant psychopathology, temazepam 10-20 mg, triazolam 0.125-0.25 mg and for occasional use, diazepam 5-10 mg, provide the initial approach. Flurazepam hydrochloride 15-30 mg, nitrazepam 5-10 mg and flunitrazepam 1 mg and above, have persistent residual effects and should be reserved for refractory patients, and for those in whom some impairment of performance the next day would be acceptable. 4 There is little or no evidence to suggest that the proper use of the short-acting hypnotics, triazolam and temazepam, leads to a worsening of sleep on withdrawal. However, some benzodiazepines may lead to disturbances of sleep and/or rebound insomnia, and nitrazepam and flunitrazepam may be implicated.
Collapse
|
40
|
Kales A, Scharf MB, Kales JD, Soldatos CR. Response
: Rebound Insomnia. Science 1980; 208:424. [PMID: 17843621 DOI: 10.1126/science.208.4442.424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
41
|
|
42
|
|
43
|
Ogura C, Nakazawa K, Majima K, Nakamura K, Ueda H, Umezawa Y, Wardell WM. Residual effects of hypnotics: triazolam, flurazepam, and nitrazepam. Psychopharmacology (Berl) 1980; 68:61-5. [PMID: 6104840 DOI: 10.1007/bf00426651] [Citation(s) in RCA: 38] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The residual effects of three hypnotics were investigated by the method of 24-h polygraphy (EEG, EMG, and EOG). The drugs were triazolam 0.25 mg and 0.5 mg, flurazepam 15 mg and 30 mg, nitrazepam 5 mg and 10 mg, and placebo. The subjects were healthy volunteers, eight men and eight women with an average age of 34.3 years. The number of total polygraphic records was 77. Triazolam 0.25 mg and 0.5 mg, flurazepam 30 mg, and nitrazepam 10 mg showed definited sleep inducing and sleep maintenance effects in night recordings. Flurazepam 15 mg and 30 mg and nitrazepam 5 mg and 10 mg were followed by residual effects in morning, afternoon and evening recording periods on the day after the administrations of the hypnotics. However, no effects were seen on the day after the administration of triazolam 0.25 mg and 0.5 mg except for some slight residual effects in the morning. Thus triazolam 0.25 mg and 0.5 mg produces less residual effect than do flurazepam 15 mg and 30 mg, and nitrazepam 5 mg and 10 mg, and 24-h polygraphy is useful for measuring the residual effects of hypnotics.
Collapse
|
44
|
Kales A, Scharf MB, Soldatos CR, Bixler EO. Clinical evaluation of hypnotic drugs: contributions from sleep laboratory studies. J Clin Pharmacol 1979; 19:329-36. [PMID: 383750 DOI: 10.1002/j.1552-4604.1979.tb02489.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The most thorough and clinically relevant approach to hypnotic drug evaluation is one that balances the strengths and weaknesses of clinical trials and sleep laboratory evaluations. Advantages of clinical trials include the ability to evaluate large numbers of subjects and specific target groups and to thoroughly assess and quantify a drug's side effects, whereas sleep laboratory studies are very limited in all of these areas. Sleep laboratory studies however provide a rigorous, precise, and comprehensive profile of a drug's activity since there is more control over experimental variables and measurements are objective as well as continuous throughout the night. These benefits offset the shortcomings of clinical trials, which include a lack of objective measurements, less control over experimental variables, failure to evaluate a drug's effectiveness with continued use, and inattention to drug interaction and withdrawal effect. Several basic principles derived from sleep laboratory findings have been incorporated into both the clinical trials and sleep laboratory evaluations recommended in the new FDA Guidelines for the Clinical Evaluation of Hypnotic Drugs. These principles include provision for adequate baseline and withdrawal periods, use of multiple consecutive drug nights to assess a drug's effectiveness with continued use, and inclusion of an adequate washout period when a cross-over design is used. The guidelines do not emphasize either clinical trials or sleep laboratory studies at the expense of each other, but rather stress their complementary utilization.
Collapse
|
45
|
Church MW, Johnson LC. Mood and performance of poor sleepers during repeated use of flurazepam. Psychopharmacology (Berl) 1979; 61:309-16. [PMID: 36646 DOI: 10.1007/bf00432277] [Citation(s) in RCA: 59] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|